JPWO2020076789A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076789A5 JPWO2020076789A5 JP2021519612A JP2021519612A JPWO2020076789A5 JP WO2020076789 A5 JPWO2020076789 A5 JP WO2020076789A5 JP 2021519612 A JP2021519612 A JP 2021519612A JP 2021519612 A JP2021519612 A JP 2021519612A JP WO2020076789 A5 JPWO2020076789 A5 JP WO2020076789A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- aureus
- binding fragment
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims description 365
- 108090001123 antibodies Proteins 0.000 claims description 365
- 239000000427 antigen Substances 0.000 claims description 362
- 108091007172 antigens Proteins 0.000 claims description 362
- 102000038129 antigens Human genes 0.000 claims description 362
- 239000000203 mixture Substances 0.000 claims description 129
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 95
- 101700015696 PHL12 Proteins 0.000 claims description 92
- 101700005515 SCX Proteins 0.000 claims description 92
- 239000002776 alpha toxin Substances 0.000 claims description 92
- 101700027420 hly Proteins 0.000 claims description 92
- 101700005116 plc Proteins 0.000 claims description 92
- 101700017245 clfA Proteins 0.000 claims description 66
- XEBKSQSGNGRGDW-YFHOEESVSA-N 9,10-DiHOME Chemical compound CCCCC\C=C/CC(O)C(O)CCCCCCCC(O)=O XEBKSQSGNGRGDW-YFHOEESVSA-N 0.000 claims description 56
- 101700070063 lktA Proteins 0.000 claims description 55
- 101700063372 ltxA Proteins 0.000 claims description 55
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 208000008960 Diabetic Foot Diseases 0.000 claims description 19
- 230000035693 Fab Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000002458 infectious Effects 0.000 claims description 8
- 230000036499 Half live Effects 0.000 claims description 7
- 102000018358 Immunoglobulins Human genes 0.000 claims description 7
- 108060003951 Immunoglobulins Proteins 0.000 claims description 7
- 206010031252 Osteomyelitis Diseases 0.000 claims description 7
- 206010062255 Soft tissue infection Diseases 0.000 claims description 7
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 7
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 7
- 206010060968 Arthritis infective Diseases 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 6
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 6
- 150000002019 disulfides Chemical class 0.000 claims description 6
- 206010003997 Bacteraemia Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 210000003141 Lower Extremity Anatomy 0.000 claims description 4
- 206010048038 Wound infection Diseases 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 230000003115 biocidal Effects 0.000 claims description 4
- 206010040872 Skin infection Diseases 0.000 claims description 3
- 231100000765 Toxin Toxicity 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000003628 erosive Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000003902 lesions Effects 0.000 claims description 2
- 230000001662 opsonic Effects 0.000 claims description 2
- 206010064687 Device related infection Diseases 0.000 claims 2
- 230000005591 charge neutralization Effects 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004851 Immunoglobulin G Human genes 0.000 description 19
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229940012952 Fibrinogen Drugs 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 102100014838 FCGRT Human genes 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743490P | 2018-10-09 | 2018-10-09 | |
| US62/743,490 | 2018-10-09 | ||
| US201962833297P | 2019-04-12 | 2019-04-12 | |
| US62/833,297 | 2019-04-12 | ||
| PCT/US2019/055143 WO2020076789A2 (fr) | 2018-10-09 | 2019-10-08 | Combinaisons d'anticorps anti-staphylococcus aureus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512647A JP2022512647A (ja) | 2022-02-07 |
| JPWO2020076789A5 true JPWO2020076789A5 (fr) | 2022-10-18 |
Family
ID=70051346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519612A Ceased JP2022512647A (ja) | 2018-10-09 | 2019-10-08 | 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11168133B2 (fr) |
| EP (1) | EP3864041A2 (fr) |
| JP (1) | JP2022512647A (fr) |
| KR (1) | KR20210072057A (fr) |
| CN (1) | CN113164602A (fr) |
| AU (1) | AU2019357983A1 (fr) |
| BR (1) | BR112021006622A2 (fr) |
| CA (1) | CA3115633A1 (fr) |
| MX (1) | MX2021004173A (fr) |
| TW (1) | TW202035443A (fr) |
| WO (1) | WO2020076789A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2698131C2 (ru) * | 2012-11-06 | 2019-08-22 | МЕДИММЬЮН, ЭлЭлСи | Антитела к поверхностным детерминантам s. aureus |
| CN112672788A (zh) | 2018-07-24 | 2021-04-16 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌凝集因子a(clfa)的抗体 |
| AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| JP7459075B2 (ja) * | 2018-10-09 | 2024-04-01 | メディミューン，エルエルシー | スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 |
| EP4146264A4 (fr) * | 2020-05-07 | 2024-07-24 | Pliant Therapeutics Inc | Traitement de maladies respiratoires avec des composés acides aminés |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| IL157041A0 (en) | 2001-01-26 | 2004-02-08 | Inhibitex Inc | Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| ATE458006T1 (de) | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| EP2360186B1 (fr) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anticorps dirigés contre la sélectine P |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| MX2008015814A (es) | 2006-06-12 | 2009-01-12 | Nabi Biopharmaceuticals | Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus. |
| JP2010520748A (ja) | 2007-02-20 | 2010-06-17 | アナプティスバイオ インコーポレイティッド | 体細胞超変異系 |
| PT2188313T (pt) | 2007-08-21 | 2017-12-12 | Amgen Inc | Proteínas de ligação ao antigénio c-fms humano |
| EP2185190B1 (fr) | 2007-08-31 | 2015-06-24 | University Of Chicago | Procédés et compositions associées pour immuniser contre des maladies et des états staphylococciques des poumons |
| US20110152173A1 (en) | 2008-07-02 | 2011-06-23 | Emergent Product Development Seattle ,LLC | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| EP2208787A1 (fr) | 2009-01-19 | 2010-07-21 | Université de Liège | Polypeptide d'alpha-hémolysine recombinant de Staphylococcus aureus doté d'une suppression dans le domaine de la branche et des insertions de séquences hétérologues |
| AU2010208125B2 (en) | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| PL3444268T3 (pl) | 2010-05-05 | 2022-04-19 | New York University | Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania |
| AU2012214531C1 (en) | 2011-02-08 | 2021-07-29 | Medimmune, Llc | Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use |
| RU2698131C2 (ru) | 2012-11-06 | 2019-08-22 | МЕДИММЬЮН, ЭлЭлСи | Антитела к поверхностным детерминантам s. aureus |
| ES2912267T3 (es) | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| CN105873946A (zh) | 2013-10-17 | 2016-08-17 | 阿尔萨尼斯生物科学有限责任公司 | 交叉反应性金黄色葡萄球菌抗体序列 |
| EP3888690A3 (fr) | 2014-05-16 | 2021-10-20 | MedImmune, LLC | Molécules présentant une altération de liaison de récepteur fc néonatal ayant des propriétés thérapeutiques et diagnostiques améliorées |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| JP2018513168A (ja) * | 2015-04-17 | 2018-05-24 | アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤 |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| CN112672788A (zh) | 2018-07-24 | 2021-04-16 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌凝集因子a(clfa)的抗体 |
| JP7459075B2 (ja) | 2018-10-09 | 2024-04-01 | メディミューン，エルエルシー | スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 |
| AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
-
2019
- 2019-10-08 AU AU2019357983A patent/AU2019357983A1/en not_active Abandoned
- 2019-10-08 US US16/596,388 patent/US11168133B2/en active Active
- 2019-10-08 BR BR112021006622-5A patent/BR112021006622A2/pt unknown
- 2019-10-08 MX MX2021004173A patent/MX2021004173A/es unknown
- 2019-10-08 KR KR1020217013653A patent/KR20210072057A/ko unknown
- 2019-10-08 WO PCT/US2019/055143 patent/WO2020076789A2/fr active Application Filing
- 2019-10-08 CN CN201980078574.1A patent/CN113164602A/zh active Pending
- 2019-10-08 EP EP19871705.0A patent/EP3864041A2/fr not_active Withdrawn
- 2019-10-08 JP JP2021519612A patent/JP2022512647A/ja not_active Ceased
- 2019-10-08 TW TW108136341A patent/TW202035443A/zh unknown
- 2019-10-08 CA CA3115633A patent/CA3115633A1/fr active Pending
-
2021
- 2021-10-01 US US17/491,889 patent/US20220089699A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11203633B2 (en) | Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv | |
| US20050288491A1 (en) | Super-humanized antibodies against respiratory syncytial virus | |
| JP2022031635A5 (fr) | ||
| AU2002368077B2 (en) | Super humanized antibodies | |
| JP2020062036A5 (fr) | ||
| JP2022105178A (ja) | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症を治療および予防するための組成物および方法 | |
| US8653242B2 (en) | Therapeutic antibodies against flagellated Pseudomonas aeruginosa | |
| US20150284450A1 (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules | |
| JP2020513791A5 (fr) | ||
| JP2011509245A5 (fr) | ||
| JP2023134618A5 (fr) | ||
| JP2020514277A5 (fr) | ||
| JP2020513759A5 (fr) | ||
| JP2014525736A (ja) | ＩｇＥに対する免疫グロブリン単一可変ドメイン | |
| JP2024016024A5 (fr) | ||
| US20170183397A1 (en) | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof | |
| JP2016501877A5 (fr) | ||
| JP4452884B2 (ja) | 抗体およびその利用 | |
| JPWO2022114163A5 (fr) | ||
| JPWO2020076789A5 (fr) | ||
| JPWO2022044573A5 (fr) | ||
| JP2020533022A5 (fr) | ||
| JPWO2020076790A5 (fr) | ||
| RU2021112346A (ru) | Комбинации антител к staphylococcus aureus | |
| JP2022535264A (ja) | クロストリジウム・ディフィシルａ毒素およびｂ毒素に対するヒト化四重特異的８価抗体 |